

We believe Australian patients have the right to high quality cost effective medicines

October 2016



#### Disclaimer

This presentation has been prepared by AusCann Group Holdings Ltd ACN 601 953 860 ("Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company or in TW Holdings Limited ACN 008 095 207 ("TWH"). You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or be TWH or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company or TWH. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company nor TWH, nor their respective related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company or TWH.

#### **Future matters**

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company and TWH.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company and TWH may be influenced by a number of factors, many of which are outside the control of the Company and TWH. No representation or warranty, express or implied, is made by the Company or TWH, or any of their respective directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company and TWH's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company or TWH warrants or represents that the actual results, performance or achievements will be as expected, planned or intended.

Without limiting the above, the proposed agreement whereby TWH will acquire the Company is subject to various terms and conditions. The Company and TWH make no representation regarding the fulfilment of the conditions and if so when.

#### тwн

TWH was not involved in the preparation of any part of this presentation and did not authorise or cause the issue of this presentation. TWH and its directors, officers, employees, advisers and agents make no express or implied representation or warranty in relation to the Company or this presentation. No statement contained in this presentation is authorized by or based on a statement or representation by TWH or its directors, officers, employees, advisers or agents. To the fullest extent permitted by law, TWH expressly disclaims and takes no responsibility for any materials in or omissions from this presentation.

## **MEDICAL CANNABIS**

- Cannabis is one of humanity's oldest crops
  - > 8,000 BCE ancestors of Japanese Jomon culture
  - > Chinese records of medicinal use 2700 BCE
- > Efficacy shown in the following conditions and symptoms, amongst others:
  - > Chronic pain treatment resistant neuropathic pain in particular
  - > Chemotherapy induced nausea, vomiting and appetite stimulation
  - Spasticity and spasms MS
  - > Treatment resistant epilepsy
- Medical cannabis use approved in Austria, France, Israel, Italy, Netherlands, USA (25 states), Canada, Czech Republic, North Korea, Spain & Uruguay, and Australia

🕱 AusCann

Immediate opportunities in Australia and internationally



AusCann is an Australian based company focused on medical cannabis with a strong team and international connections

- > We believe patients have the right to high quality, economical and clinically validated cannabis medicines.
- AusCann has the ability to deliver these medicines by having access to expertise and relevant intellectual property in respect to:
  - Plant genetics and breeding;
  - Cultivation and production techniques;
  - Manufacturing techniques for standardised full spectrum extracts;
  - Cannabis medicines that are currently being prescribed for patients for a range of conditions internationally; and
  - > Undertaking clinical studies in Australia.

#### **AUSCANN TEAM**

# **\* Aus**Cann



Dr Mal Washer Founding Chairman

Medical doctor and member of the Australian House of Representatives from 1998 to 2013.



Hon Cheryl Edwardes Non-executive Director

- Former Attorney-General for Western Australia
- Executive General Manager for External Affairs, Government Relations and Approvals at Hancock Prospecting.



#### Elaine Darby Founder & Managing Director

Bachelor of Science in Biochemistry & Microbiology, Honours in Molecular Biology and a Bachelor of Laws.



Bruce Linton Non- executive Director

Founder, Chairman and CEO of Canopy Growth Corporation, the largest producer of legal cannabis in North America.



#### Harry Karelis Founder & Executive Director

In excess of 24 years experience in the financial services sector including specialist med-tech private equity investing.



Bruce McHarrie Non-executive Director

Experienced senior executive with a background in the life science industry. Previously served as the Chief Financial Officer, Director of Operations and Director of Strategic Projects at WA Telethon Kids Institute



- Canopy Growth Corp largest North American producer
  - > 46 km<sup>2</sup> production area
  - >16,000 patients
- Phytoplant Research S.L Spanish cannabis breeding, cultivation and extraction expertise
- State Agriculture Biotechnology Centre/Murdoch University
- Zelda Therapeutics medicinal cannabis clinical trial company











## CANNABIS



- A broad range of medical conditions and symptoms have been shown to be alleviated by cannabis phytochemicals
- > > 104 phytocannabinoids
- > > 100 terpenes
- Synergy between the multiple cannabinoids, terpenes and flavonoids produces a greater therapeutic effect






Phytochemicals sourced from female flower buds of the cannabis plant

## **ENDOCANNABINOID SYSTEM**

Endocannabinoids - anandamide, found primarily in the brain, and 2-arachidonoyl glycerol (2-AG), found mainly in the rest of the body.

**\* Aus**Cann

> Identified cannabinoid receptors – CB1 and CB2



#### AUST MARKET SIZE




Clinically validated use	Incidence in Australia	Approx. \$M
Chemotherapy induced nausea, vomiting and appetite stimulation	67% of patients 130,000	237
Spasticity and spasms - MS	23,000	42
Neuropathic pain	7-8% of adults 1.8m	3,285
Treatment resistant epilepsy	82,000	150
Arthritis	3.85m	7,026
Chronic pain	3.2m	5,840
HIV/AIDS symptoms	27,150	50

Calculations based upon 300mg cannabinoids/day – approx. \$1825/yr

## STANDARDISED MEDICINE

# **\* Aus**Cann



## TWH RTO TRANSACTION SUMMARY



- AusCann has agreed to be 100% acquired by TV Holdings Limited (TWH)
- > 20 to 1 consolidation of TW Holding's shares (TV
- Fund raise up to 25m shares to be issued at A per share to raise up to \$5m
- > Up to 216m total shares will be on issue after RT (post-consolidation)

- Lead manager CPS Capital
- Current funds on hand \$3m

> Note: Subject to approvals

	Transaction Timeline (indicative only)	
by TW	Prospectus lodged	21 October 2016
	Offer Opens	21 October 2016
es (TWH)	EGM	31 October 2016
l at A\$0.20	Public Offer Closing Date	18 November 2016
	Settlement Date and issue of shares	2 December 2016
er RTO	TWH to relist as AusCann	9 December 2016
Capital Structure		
Shares currently on issue		30,118,121
Shares to be issued to AusCann Shareholders and Advisors		161,230,418
Public Offer		Up to 25,000,000
Total Shares		216,348,539
Performance Shares and Rights		31,024,579
Options	7,827,639	
Total Securit	255,200,757	
		and the second

## **CANOPY PARTNERSHIP**

# **\* Aus**Cann









We believe Australian patients have the right to high quality cost effective medicines